The data underlying this study is from the National Health Insurance Research Database (NHIRD), which has been transferred to the Health and Welfare Data Science Center (HWDC). Interested researchers can obtain the data through formal application to the HWDC, Department of Statistics, Ministry of Health and Welfare, Taiwan (<http://dep.mohw.gov.tw/DOS/np-2497-113.html>).

Introduction {#sec005}
============

Chronic kidney disease (CKD) and its associated neurological complications have been recognized as a major global health concern for decades \[[@pone.0191155.ref001]\]. The occurrence of cerebrovascular disease in patients with CKD is frequently due to both conventional and unconventional cardiovascular factors \[[@pone.0191155.ref002]--[@pone.0191155.ref004]\]. Increased chronic inflammation and oxidative stress, decreased nitric oxide production, and hyperhomocysteinaemia that might induce endothelium dysfunction, platelet aggregation, and vascular injury contribute to neurological insults in CKD patients \[[@pone.0191155.ref002],[@pone.0191155.ref003]\].

Uremia-associated risk factors such as uremic toxins, sodium and fluid accumulation, decreased erythropoiesis, albuminuria, impaired calcium and phosphate metabolism, and hyperparathyroidism also increase cerebrovascular disorders among CKD patients \[[@pone.0191155.ref002],[@pone.0191155.ref003]\]. Previous studies found increased risk of stroke when non-dialysis-dependent CKD progressed to end-stage renal disease (ESRD) \[[@pone.0191155.ref005]\]. However, differences in risk factors, stroke type, severity, and post-stroke outcomes between CKD and ESRD were not well investigated. Recent improvements in dialysis techniques prolong lifespans, but these uremic patients develop atherogenic changes, endothelial dysfunction, and vascular calcification \[[@pone.0191155.ref002],[@pone.0191155.ref003],[@pone.0191155.ref006]\]. Due to these changes, stroke becomes a major health issue for patients with impaired renal function \[[@pone.0191155.ref001],[@pone.0191155.ref002],[@pone.0191155.ref006],[@pone.0191155.ref007]\].

Although the incidence, prevalence, risk factors, and adverse outcomes of stroke in patients with CKD or ESRD have been reported, these studies are limited by small sample sizes \[[@pone.0191155.ref008]--[@pone.0191155.ref016]\], lack of control group \[[@pone.0191155.ref009]\] and matching procedure \[[@pone.0191155.ref008],[@pone.0191155.ref010]--[@pone.0191155.ref012]\], inadequate adjustment for potential confounders \[[@pone.0191155.ref015],[@pone.0191155.ref016]\], or focus on either CKD or ESRD population \[[@pone.0191155.ref008]--[@pone.0191155.ref016]\]. Yet the comprehensive features and stroke risk differences relating to CKD and ESRD were unclear, and renal illness's impacts on post-stroke outcomes were not known. Using Taiwan's National Health Insurance Research Database, we conducted two nationwide studies to evaluate stroke risk and mortality in patients with CKD or ESRD.

Methods {#sec006}
=======

Source of data {#sec007}
--------------

The National Health Insurance Program was implemented in March 1995 and now covers more than 99% of 23 million Taiwan residents with comprehensive health services. This database records patients' date of birth, sex, residence, and levels of insurance fees as well as medical records including physician diagnoses, prescriptions, treatment, medical expenditures, and examination records for all medical services, including outpatient care, emergency treatment, hospitalization, traditional Chinese medicine, and dental care \[[@pone.0191155.ref017],[@pone.0191155.ref018]\].

Ethical approvals {#sec008}
-----------------

Insurance reimbursement claims used in this study were from Taiwan's National Health Insurance Research Database, which was available for public access. To protect personal privacy, the electronic database was decoded with patient identifications scrambled for further public access for research. According to Taiwan National Health Research Institutes regulations, informed consent is not required because of the use of decoded and scrambled patient identification. However, this study also was evaluated and approved by the joint institutional review boards of Taipei Medical University in Taipei (TMU-JIRB-201509050) and E-Da Hospital in Kaohsiung, Taiwan (EDA-JIRB-2014012). The data underlying this study is from the National Health Insurance Research Database, which has been transferred to the Health and Welfare Data Science Center. Interested researchers can obtain the data through formal application to the Health and Welfare Data Science Center, Department of Statistics, Ministry of Health and Welfare, Taiwan (<http://dep.mohw.gov.tw/DOS/np-2497-113.html>).

Study design {#sec009}
------------

To investigate the risk of stroke in patients with ESRD, we conducted a retrospective cohort study and identified 1378 patients aged ≥20 years with ESRD (defined as receiving regular hemodialysis therapy 2--3 times per week) from the database of a sample of one million beneficiaries in 2000--2004, excluding those receiving peritoneal dialysis. Using frequency matching procedure, we selected 5512 CKD patients (with at least three occasions when physicians' primary diagnosis was CKD; case-control ratio = 1:4) and 11,024 controls (without any history of CKD or ESRD; case-control ratio = 1:8) from the same database as comparison cohorts during the same index period. For reducing the confounding bias, we further used exact matching procedure with propensity score (case-control ratio = 1:1) to select more appropriate ESRD patients (n = 320), CKD patients (n = 2758), and control group. These three cohorts had no history of stroke and were followed from 2000 until the end of 2013 to identify any new event of stroke. In the Study I, we used this representative sample of one million beneficiaries that allow us to analyze the long-term risk of stroke for control group, CKD patients and ESRD patients during the follow-up period. The purpose of Study I (the retrospective cohort study) was to investigate the risk of stroke for patients with and without CKD or ESRD.

Using reimbursement claims from the same National Health Insurance Research Database, we also conducted a nested stroke cohort study (Study II) of all stroke patients with hospitalization care between 2000 and 2010 across Taiwan. The Study II included large sample of 318,638 newly diagnosed hospitalized stroke patients aged ≥20 years that allow us to analyze enough death cases in the short-term period after stroke. The purpose of Study II is to investigate the impact of history of CKD and ESRD on the 30-day post-stroke mortality. Thirty-day in-hospital mortality after stroke was compared in stroke controls (stroke patients with no histories of CKD or ESRD), stroke patients with CKD history, and stroke patients with ESRD history.

Criteria and definitions {#sec010}
------------------------

Patient's low-income status was verified by the Ministry of Health and Welfare. The levels of residence urbanization were categorized according to population density, which was calculated by dividing population (persons) by area (in square kilometers) for each administrative unit of Taiwan. The population density was divided into quartiles and categorized into the lowest quartile, moderate (the second and third quartile), and high urbanization (the fourth quartile). We used *the International Classification of Diseases*, *Ninth Revision*, *Clinical Modification* (ICD-9-CM) to define physician diagnoses of diseases including stroke (ICD-9-CM 430--438), hypertension (ICD-9-CM 401--405), anemia (ICD-9-CM 280--285), ischemic heart disease (ICD-9-CM 410--414), diabetes (ICD-9-CM 250), mental disorders (ICD-9-CM 290--319), chronic obstructive pulmonary disease (ICD-9-CM 490--496), heart failure (ICD-9-CM 428), hyperlipidemia (ICD-9-CM 272.0, 272.2, 272.4), traumatic brain injury (ICD-9-CM 800--804, 850--854), liver cirrhosis (ICD-9-CM 571), atrial fibrillation (ICD-9-CM 427.31), peripheral vascular disease (ICD-9-CM 440, 443), and epilepsy (ICD-9-CM 345). The administration code was used to define renal dialysis (D8, D9). This study also considered use of anticoagulants, anti-hypertensive agents, and statin cardiovascular drugs. Anti-hypertensive medications included diuretics (such as Hydrochlorothiazide, Furosemide, Spironolactone), ACEI (such as Benazepril, Enalapril, Cilazapril, Fosinopril, Lisinopril, Moexipril, Quinapril, Ramipril), ARB (such as Candesartan, Eprosartan, Irbsartan, Losartan, Olmesartan, Valsartan), beta-blockers (Atennolol, Carvedilol, Labetalol, Metoprolol), CCB (Amlodipine, Cardil, Felodipine, Lacidipine, Nicardipine Nifedipine, Nisoldipine), and alpha-Blockers (Doxazosin, Prazosin, Terazosin). Anticoagulants included Warfarin, Dabigatran, Rivaroxaban, Apixaban, Heparin, Dalteparin, Enoxaparin, Nadroparine, Tinzaparin, Clopidogrel, Ticlopidine, Aspirin, Dipyridamole, Epoprostenol, Iloprost, Eptifibatide, Eptifibatide, Tirofiban, Treprostinil, Cilostazol, Ticagrelor, Dipyridamole, Cilostazol, Streptokinase, Urokinase, Edoxaban, and Fondaparinux. Statin included Simvastatin, Lovastatin, Pravastatin, Fluvastatin, Atorvastatin, Rosuvastatin, and Pitavastatin.

Statistical analysis {#sec011}
--------------------

Propensity score matched pairs analyses were used to determine associations between renal diseases (CKD and ESRD) and the primary outcome (incident event of stroke). We developed a non-parsimonious multivariable logistic regression model to estimate propensity scores for CKD patients and ESRD patients. Clinical significance guided the initial choice of covariates in this model: age, sex, low income, hypertension, anemia, ischemic heart disease, diabetes, mental disorders, chronic obstructive pulmonary disease, heart failure, hyperlipidemia, traumatic brain injury, liver cirrhosis, atrial fibrillation, peripheral vascular disease, epilepsy, anticoagulant, anti-hypertension, and statin. We matched CKD patients and ESRD patients to control group without renal diseases using a greedy matching algorithm (without replacement) with a caliper width of 0.2 SD of the log odds of the estimated propensity score. Our study used chi-square tests to compare sociodemographic characteristics and coexisting medical conditions of cohorts with and without hemodialysis. We calculated the hazard ratios (HRs) with 95% confidence intervals (CIs) for risk of stroke associated with CKD and ESRD adjusting for age, sex, low income, coexisting diseases, and medications in multivariate Cox proportional hazards regression models. We calculated sex- and age-stratified analyses for the adjusted HRs of stroke associated with hemodialysis. In the nested cohort study, the baseline characteristics and coexisting medical conditions among stroke patients with and without hemodialysis were compared using chi-square tests. The adjusted rate ratios (RRs) and 95% CIs of post-stroke mortality associated with hemodialysis were calculated in multivariate Poisson regressions with adjustment for covariates in univariate analysis. The association between post-stroke mortality and hemodialysis was also analyzed in stratification by age and sex. SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) statistical software was used for data analyses; two-sided *P* \< 0.05 indicated significant differences between groups.

Results {#sec012}
=======

There were no significant differences in age and gender between people among CKD, ESRD and control patients under the frequency matching procedure used in this retrospective cohort study ([Table 1](#pone.0191155.t001){ref-type="table"}). Proportionately more patients with CKD and ESRD than controls had low incomes, hypertension, anemia, ischemic heart disease, diabetes, mental disorders, heart failure, hyperlipidemia, liver cirrhosis, atrial fibrillation, peripheral vascular disease, epilepsy, or traumatic brain injury (all *p*-value \<0.001). Cohorts with CKD and ESRD used more anticoagulants (p\<0.0001), anti-hypertensive agents (p\<0.0001), and statins (p\<0.0001) compared with controls.

10.1371/journal.pone.0191155.t001

###### Baseline characteristics for controls and patients with CKD and ESRD.

![](pone.0191155.t001){#pone.0191155.t001g}

  ---------------------------------------------------------------------------------------------------------------
                                    Control\      CKD\         ESRD\        *P* value                  
                                    (N = 11024)   (N = 5512)   (N = 1378)                              
  --------------------------------- ------------- ------------ ------------ ----------- ----- -------- ----------
  Age, years                        n             (%)          n            (%)         n     (%)      1.0000

      20--29                        368           (3.3)        184          (3.3)       46    (3.3)    

      30--39                        848           (7.7)        424          (7.7)       106   (7.7)    

      40--49                        2232          (20.3)       1116         (20.3)      279   (20.3)   

      50--59                        2280          (20.7)       1140         (20.7)      285   (20.7)   

      60--69                        2504          (22.7)       1252         (22.7)      313   (22.7)   

      ≥70                           2792          (25.3)       1396         (25.3)      349   (25.3)   

  Sex                                                                                                  1.0000

      Female                        5768          (52.3)       2884         (52.3)      721   (52.3)   

      Male                          5256          (47.7)       2628         (47.7)      657   (47.7)   

  Low income                        298           (2.7)        232          (4.2)       109   (7.9)    \<0.0001

  Medical conditions                                                                                   

      Hypertension                  3895          (35.3)       2798         (50.8)      912   (66.2)   \<0.0001

      Anemia                        1204          (10.9)       1309         (23.8)      880   (63.9)   \<0.0001

      Ischemic heart disease        1945          (17.6)       1864         (33.8)      600   (43.5)   \<0.0001

      Diabetes                      1600          (14.5)       1522         (27.6)      571   (41.4)   \<0.0001

      Mental disorders              3258          (29.6)       2453         (44.5)      473   (34.3)   \<0.0001

      COPD                          2482          (22.5)       2001         (36.3)      333   (24.2)   \<0.0001

      Heart failure                 406           (3.7)        585          (10.6)      288   (20.9)   \<0.0001

      Traumatic brain injury        1035          (9.4)        729          (13.2)      169   (12.3)   \<0.0001

      Hyperlipidemia                1278          (11.6)       1072         (19.5)      162   (11.8)   \<0.0001

      Liver cirrhosis               517           (4.7)        514          (9.3)       139   (10.1)   \<0.0001

      Atrial fibrillation           306           (2.8)        291          (5.3)       94    (6.8)    \<0.0001

      Peripheral vascular disease   210           (1.9)        204          (3.7)       65    (4.7)    \<0.0001

      Epilepsy                      92            (0.8)        84           (1.5)       34    (2.5)    \<0.0001

  Type of medication                                                                                   

      Anticoagulant                 688           (6.2)        706          (12.8)      712   (51.7)   \<0.0001

      Anti-hypertension             2944          (26.7)       2204         (40.0)      667   (48.4)   \<0.0001

      Statin                        2046          (18.6)       1668         (30.3)      465   (33.7)   \<0.0001
  ---------------------------------------------------------------------------------------------------------------

COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease.

After propensity-score matching, there were no significant differences in age, sex, low income, medical conditions, and medications between people among CKD ([Table 2](#pone.0191155.t002){ref-type="table"}), ESRD ([Table 3](#pone.0191155.t003){ref-type="table"}) and control group.

10.1371/journal.pone.0191155.t002

###### Baseline characteristics for controls and CKD patients after matching with propensity score.

![](pone.0191155.t002){#pone.0191155.t002g}

  -----------------------------------------------------------------------------------------
                                    Control\     CKD\         *P* value            
                                    (N = 2758)   (N = 2758)                        
  --------------------------------- ------------ ------------ ----------- -------- --------
  Age, years                        n            (%)          n           (%)      1.0000

      20--29                        138          (5.0)        138         (5.0)    

      30--39                        276          (10.0)       276         (10.0)   

      40--49                        682          (24.7)       682         (24.7)   

      50--59                        591          (21.4)       591         (21.4)   

      60--69                        543          (19.7)       543         (19.7)   

      ≥70                           528          (19.1)       528         (19.1)   

  Sex                                                                              1.0000

      Female                        1425         (51.7)       1425        (51.7)   

      Male                          1333         (48.3)       1333        (48.3)   

  Low income                        28           (1.0)        28          (1.0)    1.0000

  Medical conditions                                                               

      Hypertension                  1087         (39.4)       1087        (39.4)   1.0000

      Mental disorders              1009         (36.6)       1009        (36.6)   1.0000

      COPD                          705          (25.6)       705         (25.6)   1.0000

      Ischemic heart disease        480          (17.4)       480         (17.4)   1.0000

      Diabetes                      407          (14.8)       407         (14.8)   1.0000

      Anemia                        333          (12.1)       333         (12.1)   1.0000

      Hyperlipidemia                323          (11.7)       323         (11.7)   1.0000

      Traumatic brain injury        191          (6.9)        191         (6.9)    1.0000

      Liver cirrhosis               87           (3.2)        87          (3.2)    1.0000

      Heart failure                 48           (1.7)        48          (1.7)    1.0000

      Atrial fibrillation           27           (1.0)        27          (1.0)    1.0000

      Peripheral vascular disease   8            (0.3)        8           (0.3)    1.0000

      Epilepsy                      3            (0.1)        3           (0.1)    1.0000

  Type of medication                                                               

      Anti-hypertension             770          (27.9)       770         (27.9)   1.0000

      Statin                        514          (18.6)       514         (18.6)   1.0000

      Anticoagulant                 87           (3.2)        87          (3.2)    1.0000
  -----------------------------------------------------------------------------------------

COPD, chronic obstructive pulmonary disease

10.1371/journal.pone.0191155.t003

###### Baseline characteristics for controls and ESRD patients after matching with propensity score.

![](pone.0191155.t003){#pone.0191155.t003g}

  ---------------------------------------------------------------------------------------
                                    Control\    ESRD\       *P* value            
                                    (N = 320)   (N = 320)                        
  --------------------------------- ----------- ----------- ----------- -------- --------
  Age, years                        n           (%)         n           (%)      1.0000

      20--29                        9           (2.8)       9           (2.8)    

      30--39                        16          (5.0)       16          (5.0)    

      40--49                        60          (18.8)      60          (18.8)   

      50--59                        64          (20.0)      64          (20.0)   

      60--69                        72          (22.5)      72          (22.5)   

      ≥70                           99          (30.9)      99          (30.9)   

  Sex                                                                            1.0000

      Female                        161         (50.3)      161         (50.3)   

      Male                          159         (49.7)      159         (49.7)   

  Low income                        2           (0.6)       2           (0.6)    1.0000

  Medical conditions                                                             

      Hypertension                  163         (50.9)      163         (50.9)   1.0000

      Anemia                        120         (37.5)      120         (37.5)   1.0000

      Ischemic heart disease        82          (25.6)      82          (25.6)   1.0000

      Diabetes                      75          (23.4)      75          (23.4)   1.0000

      Mental disorders              78          (24.4)      78          (24.4)   1.0000

      COPD                          54          (16.9)      54          (16.9)   1.0000

      Traumatic brain injury        18          (5.6)       18          (5.6)    1.0000

      Hyperlipidemia                15          (4.7)       15          (4.7)    1.0000

      Liver cirrhosis               13          (4.1)       13          (4.1)    1.0000

      Heart failure                 7           (2.2)       7           (2.2)    1.0000

      Atrial fibrillation           3           (0.9)       3           (0.9)    1.0000

      Peripheral vascular disease   0           (0.0)       0           (0.0)    1.0000

      Epilepsy                      0           (0.0)       0           (0.0)    1.0000

  Type of medication                                                             

  Anti-hypertension                 107         (33.4)      107         (33.4)   1.0000

      Anticoagulant                 54          (16.9)      54          (16.9)   1.0000

      Statin                        46          (14.4)      46          (14.4)   1.0000
  ---------------------------------------------------------------------------------------

COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease.

[Fig 1](#pone.0191155.g001){ref-type="fig"}. shows the HR of stroke for patients with ESRD was 2.39 (95% CI 1.98--2.87) during the follow-up period compared with control cohort. The association between ESRD and risk of stroke was also significant in both sexes and all age groups analyzed: males (HR 2.73), females (HR 2.13), 20--39 years (HR 3.73), 40--49 years (HR 2.61), 50--59 years (HR 2.96), 60--69 years (HR 2.52), and ≥70 years (HR 1.68). Among ESRD patients, hypertension (HR 2.71), diabetes (HR 3.89), and liver cirrhosis (HR 2.42) were significant factors contributing to the risk of stroke. Patients with CKD had increased risk of stroke during the follow-up period (HR 1.49, 95% CI 1.32--1.68). Risk of stroke was associated with CKD in females (HR 1.52), males (HR 1.45), and every age group. Among patients with CKD, hypertension (HR 1.62) and diabetes (HR 1.84) increased risk of stroke.

![Incidence and risk of stroke for controls, CKD patients, and ESRD patients.\
CI, confidence interval; CHF, heart failure; ESRD, end-stage renal disease; HR, hazard ratio; IHD, ischemic heart disease. Incidence showed per 1000 person-years. Compared with control group (n = 11024), all hazard rations adjusted for all covariates listed in [Table 1](#pone.0191155.t001){ref-type="table"} in 17 multivariate Cox proportional hazard models. Under the consideration of death as a competing risk, the hazard ratios of stroke for CKD patients and ESRD patients were 1.45 (95% CI 1.27--1.66) and 2.22 (95% CI 1.79--2.76), respectively. After matching with propensity score by all covariates listed in [Table 1](#pone.0191155.t001){ref-type="table"}, the hazard ratios of stroke for CKD patients and ESRD patients were 1.51 (95% CI 1.24--1.85) and 2.08 (95% CI 1.32--3.26), respectively. The interaction terms of ESRD\*sex (p\<0.0001), ESRD\*anemia (p\<0.0001), ESRD\*ischemic heart disease (p\<0.0001), ESRD\*diabetes (p\<0.0001), ESRD\*mental disorders (p = 0.0002), ESRD\*chronic obstructive pulmonary disease (p = 0.0021), ESRD\*heart failure (p = 0.0020), ESRD\*hyperlipidemia (p = 0.0002), ESRD\*liver cirrhosis (p = 0.0002) were added in the multivariate Cox proportional hazard models.](pone.0191155.g001){#pone.0191155.g001}

After propensity-score matching, the HRs of stroke for patients with CKD and ESRD were 1.51 (95% CI 1.24--1.85) and 2.08 (95% CI 1.32--3.26), respectively, during the follow-up period ([Table 4](#pone.0191155.t004){ref-type="table"}).

10.1371/journal.pone.0191155.t004

###### Incidence and risk of stroke for CKD and ESRD patients and controls.

![](pone.0191155.t004){#pone.0191155.t004g}

                          n      Person-years   Stroke events   Incidence[\*](#t004fn002){ref-type="table-fn"}   HR     (95% CI)[†](#t004fn003){ref-type="table-fn"}
  ----------------------- ------ -------------- --------------- ------------------------------------------------ ------ ----------------------------------------------
  Controls without CKD    2758   29827          168             5.63                                             1.00   (reference)
  CKD patients            2758   28816          237             8.22                                             1.51   (1.24--1.85)
  Controls without ESRD   320    3347           30              8.96                                             1.00   (reference)
  ESRD patients           320    2850           52              18.2                                             2.08   (1.32--3.26)

CI, confidence interval; CKD, chronic kidney disease; ESRD, end-stage renal disease; HR, hazard ratio

\*Per 1000 person-years.

†Adjusted all covariates listed in [Table 1](#pone.0191155.t001){ref-type="table"} in the multivariate Cox's proportional hazard models.

[Table 5](#pone.0191155.t005){ref-type="table"} shows baseline characteristics of newly diagnosed stroke patients among CKD, ESRD and control cohorts. Compared with controls, ESRD was associated with higher proportions of females (*p*\<0.0001), low income (*p*\<0.0001), hemorrhagic stroke (*p*\<0.0001), diabetes (*p*\<0.0001), ischemic heart disease (*p*\<0.0001), chronic obstructive pulmonary disease (*p*\<0.0001), heart failure (*p*\<0.0001), anemia (*p*\<0.0001), hyperlipidemia (*p*\<0.0001), traumatic brain injury (*p* = 0.0497), liver cirrhosis (*p*\<0.0001), peripheral vascular disease (*p*\<0.0001), and epilepsy (*p*\<0.0001). This ESRD group also used more medications than controls, specifically anti-hypertension drugs (*p*\<0.0001), statins (*p*\<0.0001), and anticoagulants (*p*\<0.0001). Stroke patients with CKD had higher proportions of older people, other stroke subtypes, hypertension, diabetes, ischemic heart disease, mental disorders, chronic obstructive pulmonary disease, heart failure, anemia, hyperlipidemia, traumatic brain injury, atrial fibrillation, and peripheral vascular disease compared with stroke controls (all *p*\<0.0001).

10.1371/journal.pone.0191155.t005

###### Baseline characteristics of hospitalized stroke patients with CKD and ESRD.

![](pone.0191155.t005){#pone.0191155.t005g}

  ------------------------------------------------------------------------------------------------------------------------------------------
                               Stroke controls (N = 300,300)   Stroke with CKD\   Stroke with ESRD\   *P* value                   
                                                               (N = 12340)        (N = 5998)                                      
  ---------------------------- ------------------------------- ------------------ ------------------- ----------- ------ -------- ----------
  Gender                       n                               (%)                n                   (%)         n      (%)      \<0.0001

      Female                   124,440                         (41.4)             4973                (40.3)      3093   (51.6)   

      Male                     175,860                         (58.6)             7367                (59.7)      2905   (48.4)   

  Age                                                                                                                             \<0.0001

      20--29                   2473                            (0.8)              34                  (0.3)       26     (0.4)    

      30--39                   8198                            (2.7)              156                 (1.3)       101    (1.7)    

      40--49                   27,849                          (9.3)              559                 (4.5)       498    (8.3)    

      50--59                   53,369                          (17.8)             1458                (11.8)      1360   (22.7)   

      60--69                   69,938                          (23.3)             2542                (20.6)      1735   (28.9)   

      70--79                   87,125                          (29.0)             4667                (37.8)      1672   (27.9)   

      ≥80                      51,348                          (17.1)             2924                (23.7)      606    (10.1)   

  Low income                   15,160                          (5.1)              721                 (5.8)       460    (7.7)    \<0.0001

  Urbanization                                                                                                                    0.0015

      Low                      3748                            (1.3)              138                 (1.1)       67     (1.1)    

      Moderate                 85,473                          (28.5)             3461                (28.1)      1577   (26.3)   

      High                     211,079                         (70.3)             8741                (70.8)      4354   (72.6)   

  Teaching hospital            271,636                         (90.5)             10911               (88.4)      5542   (92.4)   \<0.0001

  Ownership of hospital                                                                                                           \<0.0001

      Private                  224604                          (74.8)             8847                (71.7)      4514   (75.3)   

      Public                   75696                           (25.2)             3493                (28.3)      1484   (24.7)   

  Level of hospital                                                                                                               \<0.0001

      Medical center           91588                           (30.5)             3935                (31.9)      2023   (33.7)   

      Regional hospital        142557                          (47.5)             5394                (43.7)      2832   (47.2)   

      Local hospital           66155                           (22.0)             3011                (24.4)      1143   (19.1)   

  Type of stroke                                                                                                                  \<0.0001

      Hemorrhagic              68,799                          (22.9)             2346                (19.0)      2062   (34.4)   

      Ischemic                 179,443                         (59.8)             7379                (59.8)      3106   (51.8)   

      Others                   52,058                          (17.3)             2615                (21.2)      830    (13.8)   

  Coexisting diseases                                                                                                             

      Hypertension             142,388                         (47.4)             7715                (62.5)      2809   (46.8)   \<0.0001

      Diabetes                 67,751                          (22.6)             4308                (34.9)      2732   (45.6)   \<0.0001

      Ischemia heart disease   40,606                          (13.5)             3197                (25.9)      1586   (26.4)   \<0.0001

      Mental disorder          49,641                          (16.5)             3086                (25.0)      1021   (17.0)   \<0.0001

      COPD                     46,501                          (16.5)             3348                (27.1)      833    (13.9)   \<0.0001

      Heart failure            10,356                          (3.5)              1214                (9.8)       627    (10.5)   \<0.0001

      Anemia                   6383                            (2.1)              1093                (8.9)       582    (9.7)    \<0.0001

      Hyperlipidemia           19,433                          (6.5)              1399                (11.3)      565    (9.4)    \<0.0001

      Traumatic brain injury   14,261                          (4.8)              762                 (6.2)       326    (5.4)    \<0.0001

      Liver cirrhosis          3700                            (1.2)              271                 (2.2)       153    (2.6)    \<0.0001

      Atrial fibrillation      5061                            (1.7)              365                 (3.0)       116    (1.9)    \<0.0001

      PVD                      3091                            (1.0)              263                 (2.1)       116    (1.9)    \<0.0001

      Epilepsy                 1076                            (0.4)              34                  (0.3)       40     (0.7)    0.0001

  Types of medication                                                                                                             

      Anti-hypertension        62802                           (20.9)             4123                (33.4)      2053   (34.2)   \<0.0001

      Statin                   37637                           (12.5)             3106                (25.2)      1633   (27.2)   \<0.0001

      Anticoagulant            7343                            (2.5)              545                 (4.4)       448    (7.5)    \<0.0001
  ------------------------------------------------------------------------------------------------------------------------------------------

COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; PVD, peripheral vascular disease.

Thirty-day post-stroke mortality associated with CKD was (RR 1.44, 95% CI 1.33--1.56). This association was significant in females (HR 1.49), males (HR 1.41), and every age group ([Table 6](#pone.0191155.t006){ref-type="table"}). Among hospitalized stroke patients, the RR of post-stroke mortality in ESRD cohort was 2.62 (95% CI 2.43--2.82) compared with control group. Post-stroke mortality was associated with hemodialysis in male (RR 2.56) and female (RR 2.67) stroke patients. The corresponding association of mortality was also significant in stroke patients aged 20--49 years (RR 2.64), 50--59 years (RR 3.03), 60--69 years (RR 2.63), 70--79 years (RR 2.44), and ≥80 years (RR 2.01). Among stroke patients with CKD or ESRD, anemia (HR 1.94 vs. 3.34), ischemic heart disease (HR 1.50 vs. 3.12), diabetes (HR 1.49 vs. 3.24), heart failure (HR 1.79 vs. 2.33), and liver cirrhosis (HR 2.24 vs. 2.64) were contributors to 30-day post-stroke mortality.

10.1371/journal.pone.0191155.t006

###### Thirty-day post-stroke mortality for patients with CKD and ESRD.

![](pone.0191155.t006){#pone.0191155.t006g}

                                                                n         deaths   mortality, %   RR     (95% CI)[\*](#t006fn002){ref-type="table-fn"}
  ------------------------------------------------------------- --------- -------- -------------- ------ -----------------------------------------------
  Control                                                       300,300   10,129   3.4            1.00   (reference)
  CKD[†](#t006fn003){ref-type="table-fn"}                       12340     594      4.8            1.42   (1.31--1.54)
  ESRD[†](#t006fn003){ref-type="table-fn"}                      5998      667      11.1           2.58   (2.39--2.78)
  CKD + hypertension[†](#t006fn003){ref-type="table-fn"}        7715      357      4.6            1.39   (1.26--1.54)
  ESRD + hypertension[†](#t006fn003){ref-type="table-fn"}       2809      283      10.1           2.23   (1.99--2.50)
  CKD + anemia[†](#t006fn003){ref-type="table-fn"}              1093      78       7.1            1.83   (1.49--2.26)
  ESRD + anemia[†](#t006fn003){ref-type="table-fn"}             582       69       11.9           2.67   (2.14--3.34)
  CKD + IHD[†](#t006fn003){ref-type="table-fn"}                 3197      145      4.5            1.46   (1.24--1.71)
  ESRD + IHD[†](#t006fn003){ref-type="table-fn"}                1586      166      10.5           2.49   (2.15--2.89)
  CKD + diabetes[†](#t006fn003){ref-type="table-fn"}            4308      185      4.3            1.37   (1.19--1.58)
  ESRD + diabetes[†](#t006fn003){ref-type="table-fn"}           2732      291      10.7           2.49   (2.23--2.78)
  CKD + mental disorders[†](#t006fn003){ref-type="table-fn"}    3086      132      4.3            1.24   (1.04--1.47)
  ESRD + mental disorders[†](#t006fn003){ref-type="table-fn"}   1021      122      12.0           2.57   (2.18--3.03)
  CKD + COPD[†](#t006fn003){ref-type="table-fn"}                3348      141      4.2            1.24   (1.05--1.46)
  ESRD + COPD[†](#t006fn003){ref-type="table-fn"}               833       89       10.7           2.46   (2.03--2.99)
  CKD + heart failure[†](#t006fn003){ref-type="table-fn"}       1214      97       8.0            1.60   (1.21--2.13)
  ESRD + heart failure[†](#t006fn003){ref-type="table-fn"}      627       45       7.2            2.15   (1.77--2.61)
  CKD + hyperlipidemia[†](#t006fn003){ref-type="table-fn"}      1399      38       2.7            0.99   (0.73--1.35)
  ESRD + hyperlipidemia[†](#t006fn003){ref-type="table-fn"}     565       54       9.6            2.36   (1.83--3.04)
  CKD + liver cirrhosis[†](#t006fn003){ref-type="table-fn"}     271       25       9.2            1.91   (1.32--2.77)
  ESRD + liver cirrhosis[†](#t006fn003){ref-type="table-fn"}    153       19       12.4           2.09   (1.39--3.16)
  Female                                                                                                 
      Control                                                   124,440   3871     3.1            1.00   (reference)
      CKD                                                       227       227      4.6            1.47   (1.29--1.67)
      ESRD                                                      3093      319      10.3           2.62   (2.35--2.93)
  Male                                                                                                   
      Control                                                   175,860   6258     3.6            1.00   (reference)
      CKD                                                       7367      367      5.0            1.39   (1.25--1.54)
      ESRD                                                      2905      348      12.0           2.54   (2.30--2.81)
  20--49 years                                                                                           
      Control                                                   38,520    2095     5.4            1.00   (reference)
      CKD                                                       749       66       8.8            1.84   (1.46--2.31)
      ESRD                                                      625       112      17.9           2.60   (2.18--3.10)
  50--59 years                                                                                           
      Control                                                   53,369    1691     3.2            1.00   (reference)
      CKD                                                       1458      70       4.8            1.59   (1.27--2.00)
      ESRD                                                      1360      192      14.1           3.01   (2.61--3.49)
  60--69 years                                                                                           
      Control                                                   69,938    1500     2.1            1.00   (reference)
      CKD                                                       2542      80       3.2            1.38   (1.11--1.73)
      ESRD                                                      1735      144      8.3            2.60   (2.19--3.09)
  70--79 years                                                                                           
      Control                                                   87,125    2352     2.7            1.00   (reference)
      CKD                                                       4667      181      3.9            1.35   (1.17--1.57)
      ESRD                                                      1672      149      8.9            2.46   (2.10--2.89)
  ≥80 years                                                                                              
      Control                                                   51,348    2491     4.9            1.00   (reference)
      CKD                                                       2924      197      6.7            1.34   (1.17--1.55)
      ESRD                                                      606       70       11.6           2.03   (1.63--2.54)

CI, confidence interval; CKD, chronic kidney disease; IHD, ischemic heart disease; ESRD, end-stage renal disease; RR, rate ratio.

\*Adjusted for all covariates listed in [Table 3](#pone.0191155.t003){ref-type="table"} in 17 multivariate Cox proportional hazard models.

†Compared with the control group (n = 300,300).

Discussion {#sec013}
==========

Our nationwide retrospective cohort study showed patients with CKD or ESRD had nearly 1.5 to 2.5-fold risk of stroke respectively when compared with controls. Higher risk of stroke was noted when CKD or ESRD patients also had hypertension or diabetes. The nested cohort study showed CKD or ESRD patients with anemia, diabetes, ischemic heart disease or liver cirrhosis had higher post-stroke mortality than controls. In CKD patients, post-stroke mortality was highest in patients with liver cirrhosis. Mental disorders, COPD, and hyperlipidemia affected post-stroke death rates only in ESRD patients.

Hypertension, diabetes, and other traditional cardiovascular risk factors such as aging, hyperlipidemia, obesity, and smoking \[[@pone.0191155.ref002]--[@pone.0191155.ref004],[@pone.0191155.ref019]--[@pone.0191155.ref021]\] are the main causes of renal function impairment in many countries \[[@pone.0191155.ref001]\]. In our investigation, CKD or ESRD patients with hypertension or diabetes exhibited higher risk of stroke. Uremia represents a risk complex with multiple etiologies and comorbidities associated with vascular change and dialysis-related problems \[[@pone.0191155.ref017],[@pone.0191155.ref022]--[@pone.0191155.ref023]\]. Although traditional stroke risk factors are more prevalent in uremic patients than in the general population, the increased risk of stroke observed in uremic patients could not be explained solely by higher comorbidity prevalence. As CKD has been recognized as a significant predictor for stroke beyond conventional cardiovascular risk factors \[[@pone.0191155.ref003],[@pone.0191155.ref014],[@pone.0191155.ref015],[@pone.0191155.ref024],[@pone.0191155.ref025]\], the long-term effects of end-stage renal disease itself and renal replacement therapy were categorized as non-traditional risk factors, including vessel calcification, uremic toxins, frequent vascular access, and anticoagulant use during dialysis \[[@pone.0191155.ref004],[@pone.0191155.ref026]\]. These uremic-specific risk factors might induce endothelial dysfunction, platelet aggregation, and vascular calcification that increase cerebrovascular disease risks, an effect amplified if CKD progresses to ESRD \[[@pone.0191155.ref002],[@pone.0191155.ref007]\]. Similarly, cerebral and renal function are more vulnerable to vascular injury and arteriosclerotic insult with endothelial function impairment, ischemic arteriosclerosis, inadequate perfusion, neurovascular coupling, and blood-brain barrier disruption \[[@pone.0191155.ref002]\].

The exact mechanism of stroke in CKD and uremic patients remains unclear. Intracranial artery calcification, blood pressure control, and associated medical comorbidities are possible explanations \[[@pone.0191155.ref027],[@pone.0191155.ref028]\]. Furthermore, the Klotho protein was considered as a regulator of cardiovascular disease, and the progress of kidney dysfunction decreases Klotho gene expression, which might in turn impair calcium and phosphate metabolism and cell function \[[@pone.0191155.ref002]\]. Nutritional status is another stroke risk concern in chronic dialysis patients, whose serum albumin levels have been found to be lower than normal \[[@pone.0191155.ref003],[@pone.0191155.ref026],[@pone.0191155.ref029]\]. Hypoalbuminemia results in red blood cell deformity and endothelial cell dysfunction \[[@pone.0191155.ref029]\]. Cerebral blood flow and cerebral oxygenation also decreases significantly in ESRD patients, predisposing them to brain atrophy, cognitive dysfunction, and stroke \[[@pone.0191155.ref030]\]. Other possible reasons for ischemic stroke include erythropoietin-induced thromboembolic events \[[@pone.0191155.ref012],[@pone.0191155.ref026],[@pone.0191155.ref031]\], arteriovenous shunt-related steal-like influence \[[@pone.0191155.ref012]\], and hypotensive effect during the ultra-filtration stage of hemodialysis \[[@pone.0191155.ref001]\]. For hemorrhagic stroke, hypertension and routine use of heparin as anticoagulant during hemodialysis are considered major determinants of this complication \[[@pone.0191155.ref001],[@pone.0191155.ref008],[@pone.0191155.ref015]\]. Other possible risk factors for hemorrhagic stroke include impaired platelet function and polycystic kidney \[[@pone.0191155.ref003],[@pone.0191155.ref030],[@pone.0191155.ref031]\].

Comorbidities' differential impact on stroke incidence and post-stroke mortality between CKD and ESRD was an important issue that was not well investigated in previous studies. Among all listed risk factors, anemia, hyperlipidemia, and liver cirrhosis did not exhibit significant influence on stroke incidence in patients with CKD, but showed some effect in patients with ESRD. Different degrees of kidney dysfunction severity and various effects of treatment for coexisting clinical conditions may account for these discrepancies.

As hyperlipidemia is one of the traditional atherosclerotic risk factors in CKD, control of dyslipidemia might not only decrease cardiovascular events, but also delay the progression of kidney disease \[[@pone.0191155.ref032]\]. In our study, hyperlipidemia did not influence stroke incidence and post-stroke mortality significantly in patients with CKD, but had some effect in patients with ESRD. This might be attributed to higher frequency of statin use in CKD and ESRD populations. Stain had shown benefits in improving triglyceride levels, elevated low-density lipoprotein and low high-density lipoprotein in patients with CKD not requiring dialysis therapy \[[@pone.0191155.ref032]\]. Anemia is a common complication of CKD and might reach peaks when renal dysfunction progresses to ESRD \[[@pone.0191155.ref033]--[@pone.0191155.ref034]\]. Reduced oxygen transport and supply might cause cerebral ischemia and compensatory increase in cerebral blood flow. The effect of dilutional anemia in increasing cerebral blood flow was predominately higher in patients with ESRD \[[@pone.0191155.ref035]\]. The postulated mechanism can be attributed to vasodilation in response to reduced arterial oxygen tension or decreased blood viscosity \[[@pone.0191155.ref035],[@pone.0191155.ref036]\]. Although elevated CBF may compensate for anemia-induced hypoxia, cerebral oxygen delivery was still relatively low \[[@pone.0191155.ref035]\]. Furthermore, cerebrovascular response to CO2 was obviously attenuated in anemic individuals with chronic renal failure, which resulted in decreased cerebral vasodilatory reserve \[[@pone.0191155.ref036]\]. Varying degrees of anemia and compensatory response between CKD and ESRD might explain different impacts on stroke incidence. Reduced prevalence of cardiovascular complications in patients with cirrhosis had been reported in previous studies \[[@pone.0191155.ref037]\]. Impaired hemostatic and platelet function might act as a protective mechanism against ischemic events in cirrhotic patients, possibly due to decreased prevalence of abnormal supraortic flow patterns in cirrhotic populations \[[@pone.0191155.ref037]\]. In the present study, liver cirrhosis did not show significant influence on stroke incidence in patients with CKD, and exhibited similar hazard ratio to that of ESRD. Decreased coagulation components and reduced hemostatic function could account for this. Nevertheless, post-stroke mortality in CKD patients was highest when liver cirrhosis existed concurrently. Further investigation is needed to determine whether type and etiology of cirrhosis and its related pathophysiological consequences contribute to post-stroke deaths.

Chronic obstructive pulmonary disease (COPD) and mental disorders did not increase incidence of stroke in CKD and ESRD patients, but showed obvious additive effects on post-stroke mortality. COPD is characterized by chronic inflammatory response, and is a strong risk factor for CKD development and progression \[[@pone.0191155.ref038]\]. They share common atherosclerotic risk factors through systemic inflammatory processes such as hypertension and diabetes \[[@pone.0191155.ref038]\]. The possible mechanism for developing COPD was attributed to the existence of transforming growth factor (TGF)-β and inflammatory cytokine tumor necrosis factor-alpha \[[@pone.0191155.ref038]\]. Both mediators are seen as possible pathogens capable of causing atherosclerotic change in patients with COPD or CKD \[[@pone.0191155.ref038]\]. Though the assumption will still need to be confirmed, the discrepancy between stroke incidence and post-stroke mortality in patients with ESRD might be due to differences in disease severity and inflammatory response. Patients with CKD often showed global cognitive function decline and dementia as renal function deteriorated \[[@pone.0191155.ref039],[@pone.0191155.ref040]\]. Cognitive dysfunction can have multiple causes that effect metabolic and biochemical derangements in the central nervous system, including secondary hyperparathyroidism, amino acid abnormality, and uremic-induced neurotoxicity \[[@pone.0191155.ref040]\]. When kidney function deteriorates to ESRD, these pathological effects can increase post-stroke mortality when combined with mental disorders.

When anemia, diabetes, and IHD existed concurrently, post-stroke mortality was especially high in patients with either CKD or ESRD. To treat concurrent anemia, erythropoiesis-stimulating agents (ESAs) have been a main strategy to correct anemia since 1987 \[[@pone.0191155.ref033],[@pone.0191155.ref034]\]. Although such therapy may benefit CKD patients by improving quality of life and reducing transfusion frequency, it has been associated with increased risk of stroke, thrombosis, and mortality, especially among individuals with cancer and populations treated with higher doses of ESAs \[[@pone.0191155.ref033],[@pone.0191155.ref034]\]. Though our study lacked information on ESA use, this therapy is still postulated as the most likely reason for higher mortality in anemic patients with CKD or ESRD. Substantial effort must be devoted to achieving appropriate hemoglobin levels with ESA therapy. Diabetes constitutes the major cause of renal failure \[[@pone.0191155.ref001]\], and the impact of diabetes on stroke incidence and post-stroke survival in patients with CKD or ESRD should be emphasized in further research. Diabetes and ESRD have synergistic influences on cardiovascular risks such as acute myocardial complication, heart failure, and stroke \[[@pone.0191155.ref007]\]. The pathophysiological explanations for these phenomena include the combined effects of elevated blood pressure, dyslipidemia, endothelial dysfunction, oxidative stress, insulin resistance, and vascular local inflammation signaling that leads to atherosclerosis and increases the likelihood of stroke \[[@pone.0191155.ref007]\]. Cardiovascular disease and CKD constitute a vicious cycle promoting each other's occurrence and severity. This mechanism is complex, with overlapping interrelationships including upregulation of the renin-angiotensin-aldosterone axis and sympathetic nervous system in the cardiovascular system as well as fluid overloading, heart remodeling, impaired blood pressure control, and inflammatory response in patients with renal dysfunction \[[@pone.0191155.ref041]\]. In this study, ischemic heart disease and heart failure did not show additive effects on stroke incidence in patients with CKD and ESRD, perhaps because of pharmacological interventions. Anti-platelet medications, anti-coagulation drugs, NSAIDs, angiotensin converting enzyme inhibitors, calcium channel blockers, and statins were effective in reducing cardiovascular risks in patients with CKD and ESRD \[[@pone.0191155.ref033],[@pone.0191155.ref042]--[@pone.0191155.ref044]\]. Yet once stroke occurred, ischemic heart disease elevated post-stroke mortality in patients with ESRD, possibly because of the synergistic influences of cardiovascular disease and renal function impairment.

The strength of this investigation was cohort study design, larger sample size, multivariate adjustment of confounding factors, and reporting various types of stroke. However, we admit some limitations that should be considered when interpreting the results of this study. First, our study lacks information on detailed sociodemographics; on lifestyle factors like smoking, alcohol intake, nutrition and physical activity levels; on severity and duration of kidney dysfunction; on hemodialysis compliance characteristics; on changes in hemodynamic variables change; on anticoagulant management; and on results of clinical examinations. There also is a risk that we underestimated the prevalence of coexisting medical conditions and incidence of stroke because patients with minor illness might neglect to seek medical care. Third, the severity of stroke was not definedm and this might bias risk estimations associating CKD and ESRD with post-stroke mortality. Finally, residual confounding is always possible despite controlling for various possible confounders in the regression models.

In conclusion, our analysis provided comprehensive evaluation of stroke risk and post-stroke mortality in patients with CKD and ESRD and established that these renal disorders were independent risk factors for both outcomes. Further investigation is necessary to develop strategies to reduce stroke risk and post-stroke mortality in these high-risk patient populations.
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